Status:
COMPLETED
MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Prostatic Neoplasms
Eligibility:
MALE
18+ years
Phase:
PHASE1
Brief Summary
This two part study will evaluate the safety and tolerability of MK0429 in addition to assessing it's pharmacokinetic profile and pharmacodynamic response.
Eligibility Criteria
Inclusion
- Eligible patients must have:
- Prostate cancer
- Bone metastases without symptoms
- Lack of response to hormone therapy as evidenced by a rising PSA or clinical progression
Exclusion
- Prostate cancer-related bone pain
- Previously received bisphosphonate therapy (e.g. zoledronate)
- Received any investigational treatment within the last 30 days
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT00302471
Start Date
March 1 2006
End Date
October 1 2007
Last Update
April 27 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.